Why is teriparatide limited to 2 years of use?

In rats given very high doses of PTH analogs for most of their lifespans, an increased incidence of osteosarcoma (bone cancer) was observed. No increased risk has been observed in humans, but as a precaution, the FDA mandates a lifetime maximum of 2 years of teriparatide therapy. After completing teriparatide, patients typically transition to an antiresorptive agent (bisphosphonate or denosumab) to maintain bone density gains.

How is teriparatide different from bisphosphonates?

Bisphosphonates (alendronate, zoledronate) work by suppressing osteoclasts — cells that break down bone. This reduces bone loss but does not build new bone. Teriparatide is anabolic: it stimulates osteoblasts to form new bone, actually increasing bone mass and improving bone architecture. For severe osteoporosis or patients who have fractured on bisphosphonates, teriparatide is often preferred.

Treatment hubFDA ApprovedDeep Dive

Teriparatide Treatment Guide: Forteo, Bonsity, Cost and Provider Paths

In the United States, Teriparatide is an FDA-approved peptide therapy. Osteoporosis in postmenopausal women at high risk of fracture; primary hypogonadal osteoporosis in men; glucocorticoid-induced osteoporosis

Published: Apr 27, 2026Updated: Apr 27, 2026Medically reviewed: Apr 27, 2026Current

Medically Reviewed

This content was medically reviewed by Sarah Chen, MD, Board-Certified in Endocrinology, Diabetes, and Metabolism.

Last reviewed: April 27, 2026

Overview

Teriparatide is a recombinant human parathyroid hormone analog (PTH 1-34) and the first anabolic (bone-building) agent approved by the FDA for osteoporosis. Unlike bisphosphonates which suppress bone resorption, teriparatide stimulates osteoblast activity and new bone formation.

Approved Product Paths

Forteo

Branded teriparatide pathway. Osteoporosis in postmenopausal women at high risk of fracture; primary hypogonadal osteoporosis in men; glucocorticoid-induced osteoporosis

Bonsity

Branded teriparatide pathway. Osteoporosis in postmenopausal women at high risk of fracture; primary hypogonadal osteoporosis in men; glucocorticoid-induced osteoporosis

Benefits

•Only FDA-approved anabolic (bone-building) osteoporosis drug
•Significant reduction in vertebral and non-vertebral fractures
•Increases bone mineral density at spine and hip
•Approved for glucocorticoid-induced osteoporosis

Side Effects & Friction

•Nausea, dizziness, leg cramps
•Hypercalcemia (transient, dose-dependent)
•Injection site reactions
•Osteosarcoma risk in rats (black box warning; limit human use to 2 years)

Administration Routes

Subcutaneous injection

Cost Reality

Teriparatide costs vary by brand, pharmacy, and insurance design. As an FDA-approved medication, coverage may be available but often requires prior authorization and documentation of the approved indication.

Provider Path

The highest-value next step is finding a provider experienced in healing & recovery who can evaluate whether Teriparatide fits the patient's clinical profile and insurance constraints.

How Teriparatide Works

Teriparatide is a recombinant form of human parathyroid hormone (PTH 1-34). It is the only FDA-approved anabolic osteoporosis therapy that stimulates bone formation rather than just inhibiting resorption.

Teriparatide binds to the PTH/PTHrP receptor (PTH1R) on osteoblasts and osteocytes. At intermittent daily doses, this activates Wnt signaling and RUNX2 transcription factors, stimulating osteoblast differentiation, proliferation, and activity.

The anabolic effect is dose- and schedule-dependent. Continuous PTH elevation (as in hyperparathyroidism) causes bone resorption. Intermittent daily pulses (as with teriparatide injection) favor formation over resorption, producing a net gain in bone mass and improved microarchitecture.

Teriparatide increases both cortical and trabecular bone density. It improves bone quality metrics including connectivity, plate-to-rod ratio, and cortical thickness — changes that are not fully captured by standard DXA BMD measurements.

The drug also increases intestinal calcium absorption and renal phosphate excretion, though these effects are secondary to the skeletal anabolic action.

Osteoblast activity peaks within 6-12 months. After approximately 18-24 months, bone resorption catches up and the net anabolic benefit plateaus. This is why treatment is limited to 2 years.

After stopping teriparatide, bone density gradually declines. Antiresorptive therapy (bisphosphonate or denosumab) is recommended immediately after to preserve gains.

PTH/PTHrP receptor (PTH1R)OsteoblastsOsteocytesRenal tubules

Clinical Trial Evidence

pivotal fracture trial (Neer et al)

Population: Postmenopausal women with prior vertebral fracture

N= 1,637

Duration: Median 21 months

Endpoint: New vertebral fractures

65% reduction in vertebral fractures (RR 0.35, 95% CI 0.22-0.55)
53% reduction in non-vertebral fragility fractures (RR 0.47, 95% CI 0.25-0.88)
BMD increased 9-13% at lumbar spine
BMD increased 3-6% at femoral neck

Male osteoporosis trial

Population: Men with idiopathic or hypogonadal osteoporosis

N= 437

Duration: 11 months

Endpoint: Change in BMD

Lumbar spine BMD increased 5.9% vs 0.5% placebo
Femoral neck BMD increased 1.5% vs 0.3% placebo
Well tolerated in male population

Glucocorticoid-induced osteoporosis

PMID: 15564556

Population: Patients on chronic glucocorticoids with osteoporosis

N= 428

Duration: 18 months

Endpoint: Change in BMD

Lumbar spine BMD increased 7.2% vs 3.4% with alendronate
Superior to alendronate in patients on glucocorticoids

Dosing & Administration

Postmenopausal osteoporosis, male osteoporosis, glucocorticoid-induced osteoporosis (Forteo)Subcutaneous · Once daily

Starting: 20 mcg once daily

Titration: No titration; fixed dose

Maintenance: 20 mcg once daily

Maximum: 20 mcg once daily

•Inject subcutaneously into thigh or abdomen
•Take at same time each day
•Patient should sit or lie down if dizziness occurs after injection
•Store in refrigerator; do not freeze
•Single-use prefilled pen delivers 28 doses; discard after 28 days

Side Effect Profile

Common

Nauseamild8%

Usually transient

Dizzinessmild8%

Orthostatic; advise sitting after injection

Leg crampsmild3%

Usually nocturnal

Headachemild8%

Transient

Metabolic

Hypercalcemiamoderate3%

Usually mild and transient; check serum calcium

Hyperuricemiamild4%

Usually asymptomatic

Rare but serious

Osteosarcoma (theoretical)severeRare in humans

Observed in rats at 3-60x human dose; no proven human cases; avoid in patients with Paget disease or prior radiation

Contraindications & Warnings

Do Not Use

Paget disease of bone
Prior radiation therapy involving the skeleton
Bone metastases or skeletal malignancies
Hypercalcemia
Pregnancy or breastfeeding
Patients at increased baseline risk for osteosarcoma

Important Warnings

Boxed warning for osteosarcoma risk based on rat studies at supraphysiologic doses. No confirmed human cases. Avoid in patients with Paget disease, prior skeletal radiation, or unexplained alkaline phosphatase elevation.
Treatment limited to 2 years cumulative lifetime due to theoretical osteosarcoma concern and plateauing anabolic effect
Hypercalcemia may occur; monitor serum calcium
Urolithiasis risk may increase in predisposed patients
Must follow with antiresorptive therapy after discontinuation to preserve bone gains

Drug Interactions

Drug	Interaction	Severity	Mechanism
Bisphosphonates	Should not be combined simultaneously	major	Bisphosphonates inhibit resorption and may blunt anabolic signal; sequence teriparatide first, then bisphosphonate
Denosumab	Should not be combined simultaneously	major	Same rationale as bisphosphonates; sequence anabolic first, then antiresorptive
Calcium supplements	May increase hypercalcemia risk	minor	Additive calcium load
Digitalis	Hypercalcemia increases toxicity risk	moderate	Teriparatide may raise serum calcium transiently

Monitoring Requirements

Serum calcium at 1 month, 3 months, and every 6 months
DXA BMD at 12 and 24 months
Bone turnover markers (P1NP, CTX) optional
Signs of hypercalcemia (fatigue, confusion, polyuria)
Transition plan to antiresorptive therapy before month 24

How Teriparatide Compares

MechanismTeriparatide advantage

Teriparatide: Anabolic (builds bone)

Alendronate (bisphosphonate): Antiresorptive (prevents loss)

Anabolic therapy produces greater fracture reduction in severe osteoporosis

BMD increaseTeriparatide advantage

Teriparatide: 9-13% spine

Alendronate: 5-8% spine

Teriparatide produces larger BMD gains

CostAlendronate advantage

Teriparatide: ~$3,500/month

Alendronate: ~$20/month (generic)

Bisphosphonates are far less expensive

MechanismTeriparatide advantage

Teriparatide: Anabolic

Denosumab: Antiresorptive (RANKL antibody)

Different mechanism; some patients benefit from sequential anabolic-antiresorptive approach

MechanismRomosozumab advantage

Teriparatide: PTH receptor agonist

Romosozumab: Sclerostin antibody (dual anabolic/antiresorptive)

Romosozumab may produce faster BMD gains but has cardiovascular safety questions

Evidence Quality Assessment

Overall Evidence Grade: A

A = Strong evidence from multiple large RCTs

Human RCTs: Extensive: Large pivotal fracture trial, male osteoporosis trial, glucocorticoid trial (total n>2,500)

Long-term data: Moderate: 2-year treatment data robust; long-term safety surveillance ongoing

Real-world evidence: Extensive: Years of post-marketing use with active pharmacovigilance

Regulatory status: FDA-approved for postmenopausal osteoporosis, male osteoporosis, and glucocorticoid-induced osteoporosis

Is Teriparatide Right for You?

Ideal Candidates

Postmenopausal women with severe osteoporosis (T-score ≤-3.0) or prior fragility fracture
Patients who have failed or cannot tolerate bisphosphonates
Men with osteoporosis and low bone mass
Patients on chronic glucocorticoids with rapid bone loss
Patients with very low BMD who need rapid improvement before surgery

Avoid

Paget disease of bone
Prior skeletal radiation
Active malignancy or bone metastases
Hypercalcemia
Patients unlikely to adhere to daily injection for 2 years

Use With Caution

History of urolithiasis
Mild renal impairment
Patients >75 (limited data but no specific contraindication)
Ensure patient can commit to sequential antiresorptive therapy after teriparatide completion

Cost & Insurance Deep Dive

List Price (Monthly)

~$3,500/month (Forteo); ~$4,200/month (Bonsity, authorized generic)

Cash-Pay Range

$3,000-$4,500/month without insurance

Insurance Coverage Rate

~70-85% for approved indications with proper documentation

Prior Auth Likelihood

Very high; requires DXA T-score, fracture history, and often bisphosphonate failure

Savings Programs

Forteo Patient AssistanceFree for eligible patients

Eligibility: Uninsured, income ≤400% FPL

Annual application

Manufacturer savings cardMay reduce copay significantly

Eligibility: Commercially insured

Not for government insurance

Bonsity authorized genericSlightly lower cost than Forteo

Eligibility: All patients

Same active ingredient; may improve insurance coverage

Cost-Effectiveness Notes

•Cost per fracture prevented is favorable in high-risk patients despite high drug cost
•Generic alendronate is far cheaper but less effective in severe osteoporosis
•2-year limit means total treatment cost is capped at ~$84,000
•Sequential antiresorptive therapy adds cost but is essential to preserve gains

Ready to find a teriparatide provider?

Use the provider matcher to compare treatment paths by state, coverage, budget, urgency, and intake mode before committing to a prescribing workflow.

Find a teriparatide provider

Progress Tracking Tools

Monitor health markers and outcomes during treatment.

Smart WiFi Body Scale

Tracks BMI, body fat %, and muscle mass — essential for monitoring GLP-1 progress over time.

$30–60View on Amazon

Digital Kitchen Food Scale

Precise gram-level portion tracking helps maximize weight loss results on GLP-1 therapy.

$10–20View on Amazon

Protein Shaker Bottle Set

Leak-proof mixing bottles for protein shakes — supports consistent protein intake on a smaller appetite.

$12–25View on Amazon

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Teriparatide FAQ

Sources

1. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
N Engl J Med • 2001
Claim type: clinical
View source →
2. FDA Information on Teriparatide
FDA • 2026
Claim type: regulatory
View source →

This content is for informational purposes only and does not constitute medical advice.